Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHB4 | P54760 | 4/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | WRN | Q14191 | 1/20 | 0.49 |
| ▸ | BRAF | P15056 | 2/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 7/20 | 0.46 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.44 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 2/20 | 0.43 |
| ▸ | TEK | Q02763 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | IDH2 | P48735 | 1/20 | 0.42 |
| ▸ | CSF1R | P07333 | 1/20 | 0.42 |
| ▸ | RET | P07949 | 1/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.42 |
| ▸ | FLT1 | P17948 | 1/20 | 0.42 |
| ▸ | FLT4 | P35916 | 1/20 | 0.42 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
| ▸ | FRK | P42685 | 1/20 | 0.42 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.42 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5592578 | 0.91 | TRPV1 (0.57) | EPHB4BLMBRAFTRPV1KDR | |
| SCHEMBL5592683 | 0.90 | EPHB4 (0.53) | EPHB4BRAFTRPV1KDRNAMPT | |
| SCHEMBL5592847 | 0.88 | MEN1 (0.56) | TRPV1KDRNAMPT | |
| SCHEMBL5671277 | 0.88 | EPHB4 (0.49) | EPHB4BRAFTRPV1KDRTEK | |
| SCHEMBL5586067 | 0.87 | NAMPT (0.44) | EPHB4TRPV1KDRTEKNAMPT | |
| SCHEMBL5612143 | 0.85 | EPHB4 (0.52) | EPHB4BRAFTRPV1RIPK1KDR | |
| SCHEMBL5592636 | 0.83 | TRPV1 (0.42) | EPHB4BRAFTRPV1KDRFLT1 | |
| SCHEMBL5959865 | 0.81 | EPHB4 (0.44) | EPHB4BRAFTRPV1KDRNAMPT | |
| SCHEMBL5592573 | 0.80 | MEN1 (0.49) | EPHB4TRPV1 | |
| SCHEMBL5592888 | 0.80 | EPHB4 (0.54) | EPHB4TRPV1KDRTEK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1858879-B1 | 1,3-DIARYL SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY | GILEAD CONNECTICUT INC (US) | 2012-06-06 | — | — | EP | claimed |
| CN-102267978-A | 1,3-diaryl substituted ureas as modulators of kinase activity | — | 2011-12-07 | — | — | CN | claimed |
| CN-101163691-A | 1, 3-diaryl substituted ureas as modulators of kinase activity | CGI PHARMACEUTICALS INC (US) | 2008-04-16 | — | — | CN | claimed |
| US-20060199846-A1 | Certain substituted ureas as modulators of kinase activity | GILEAD CONNECTICUT, INC. | 2006-09-07 | — | — | US | claimed |
| EP-1858879-B1 | 1,3-DIARYL SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY | GILEAD CONNECTICUT INC (US) | 2012-06-06 | — | — | EP | disclosed |
| EP-2397478-A1 | 1,3-diaryl substituted ureas as modulators of kinase activity. | CGI Pharmaceuticals, Inc. (US) | 2011-12-21 | — | — | EP | disclosed |
| EP-2397478-A1 | 1,3-diaryl substituted ureas as modulators of kinase activity. | CGI Pharmaceuticals, Inc. (US) | 2011-12-21 | — | — | EP | disclosed |
| CN-102267978-A | 1,3-diaryl substituted ureas as modulators of kinase activity | — | 2011-12-07 | — | — | CN | disclosed |
| CN-101163691-A | 1, 3-diaryl substituted ureas as modulators of kinase activity | CGI PHARMACEUTICALS INC (US) | 2008-04-16 | — | — | CN | disclosed |
| EP-1858879-A1 | 1,3-DIARYL SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY | CGI Pharmaceuticals, Inc. (US) | 2007-11-28 | — | — | EP | disclosed |
| US-20060199846-A1 | Certain substituted ureas as modulators of kinase activity | GILEAD CONNECTICUT, INC. | 2006-09-07 | — | — | US | disclosed |
| WO-2006076593-A1 | 1,3-DIARYL SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY | CGI PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199846-A1 | Certain substituted ureas as modulators of kinase activity | UCK2, CHUK, AXL | EPHB4 3357/4885BLM 4659/4885WRN 3824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.